Grant: Proof of Principle Program - Phase I
University of Toronto
$160,000.00
Preclinical evaluation of multifunctional polymer nanoparticles for targeted brain cancer therapy
FY 2013-14
Summary
Many types of cancer can spread to the brain (brain metastases) including lung cancer (40-50%) and breast cancer (15-25%). Unfortunately, people with brain metastases have very short survival times ranging from 1-2 months without treatment to 4-6 months with surgery, radiation, chemotherapy, and even with newly developed antibodies. The failure of chemotherapy and antibody treatment is mainly caused by their poor penetration into the brain and targeting the cancer cells due to a major physiological barrier, the blood-and-brain barrier (BBB) and non-specificity of the agents. Dr. Wu has discovered a new "nanomedicine" (tiny drug-carrying particles) that can cross the BBB, and selectively deliver the anticancer drug(s) in the cancer cells, while sparing the normal brain from harm. In this project, Dr. Wu will conduct systematic evaluation of the effectiveness and safety of the nanomedicine in a brain tumor model.
Department
Program
Proof of Principle Program - Phase I
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
293919
Name
Wu Xiao Yu S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Preclinical evaluation of multifunctional polymer nanoparticles for targeted brain cancer therapy
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$160,000
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Anticancer Drug Delivery; Cancer Cell Targeting; Cross Blood-Brain Barrier; Dose Tolerance; Drug Loading Capability; Efficacy; Pharmacokinetics; Polymer Nanoparticles; Preclincal Evaluation; Toxicity
Abstract
Many types of cancer can spread to the brain (brain metastases) including lung cancer (40-50%) and breast cancer (15-25%). Unfortunately, people with brain metastases have very short survival times ranging from 1-2 months without treatment to 4-6 months with surgery, radiation, chemotherapy, and even with newly developed antibodies. The failure of chemotherapy and antibody treatment is mainly caused by their poor penetration into the brain and targeting the cancer cells due to a major physiological barrier, the blood-and-brain barrier (BBB) and non-specificity of the agents. Dr. Wu has discovered a new "nanomedicine" (tiny drug-carrying particles) that can cross the BBB, and selectively deliver the anticancer drug(s) in the cancer cells, while sparing the normal brain from harm. In this project, Dr. Wu will conduct systematic evaluation of the effectiveness and safety of the nanomedicine in a brain tumor model.
Competitiondate
201309
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wu, Xiao Yu S
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $160,000~ $0~